DAIICHI SANKYO INC
SpecialtyDAIICHI SANKYO INC is a specialty pharmaceutical company focused on Oncology, Cardiovascular, Metabolic. Key products include SAVAYSA.
FDA Novel Drug Designations
(2019-2025)DAIICHI SANKYO INC at a Glance
- Growing R&D activity with 28 trials in last 2 years
- Fast trial execution (22 months median completion)
DAIICHI SANKYO INC's Key Drugs
DAIICHI SANKYO INC's core commercial portfolio centers on ENHERTU, DATROWAY, SAVAYSA, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Unresectable or metastatic HER2-positive breast cancer
Non-Small Cell Lung Cancer
Stroke
Tenosynovial Giant Cell Tumor
Acute Myeloid Leukemia
DAIICHI SANKYO INC's Recent FDA Approvals
DAIICHI SANKYO INC secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
DAIICHI SANKYO INC's Therapeutic Areas
DAIICHI SANKYO INC's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
DAIICHI SANKYO INC's Top Competitors
DAIICHI SANKYO INC's closest competitors by therapeutic-area and drug-target overlap include Merck, AstraZeneca, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
DAIICHI SANKYO INC Pipeline Snapshot
DAIICHI SANKYO INC has 202 active clinical programs from ClinicalTrials.gov — 53 Phase 3, 47 Phase 2 and 102 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ENHERTU leads revenue
- • 5 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 22/42 completed
- • Speed: 22 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges